Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.43 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.43 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.43 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.43 |
| ▸ | CBFB | Q13951 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12232835 | 0.89 | KDM4E (0.39) | NPC1KDM4EMAPTRAB9AMEN1 | |
| SCHEMBL10183716 | 0.81 | CYP1A2 (0.48) | MAPTRAB9AMEN1KMT2ALMNA | |
| SCHEMBL3637649 | 0.70 | NPC1 (0.53) | NPC1KDM4EMAPTRAB9AMEN1 | |
| SCHEMBL16923187 | 0.69 | KDM4E (0.53) | NPC1KDM4EMAPTRAB9AMEN1 | |
| SCHEMBL26581256 | 0.67 | TP53 (0.53) | NPC1KDM4EMAPTKMT2ALMNA | |
| SCHEMBL3952992 | 0.66 | KMT2A (0.60) | NPC1KDM4EMAPTRAB9AMEN1 | |
| SCHEMBL8577441 | 0.66 | MEN1 (0.68) | NPC1KDM4EMAPTRAB9AMEN1 | |
| SCHEMBL11077511 | 0.64 | MAPT (0.44) | NPC1KDM4EMAPTRAB9AMEN1 | |
| SCHEMBL8576078 | 0.64 | MEN1 (0.66) | NPC1KDM4EMAPTRAB9AMEN1 | |
| SCHEMBL7726215 | 0.64 | NPSR1 (0.86) | NPC1KDM4EMAPTRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20170283801-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2017-10-05 | — | — | US | disclosed |
| US-9708615-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9566340-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160376591-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9394540-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2016-04-14 | — | — | US | disclosed |
| US-8420799-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120214861-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120107272-A1 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110251257-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | ALNYLAM PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110201798-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110166198-A1 | RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110054160-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110027882-A1 | Methods and Compositions for Treating Neurological Disease | UNIVERSITY OF MASSACHUSETTS | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | NPC1 191/4885KDM4E 2088/4885MAPT 1247/4885 |
| US-20110054160-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | NPC1 193/4885KDM4E 3864/4885MAPT 3036/4885 |
| US-20110251257-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | NPC1 68/4885KDM4E 4076/4885MAPT 38/4885 |
| US-20110201798-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | NPC1 193/4885KDM4E 3864/4885MAPT 3036/4885 |
| US-20120214861-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | NPC1 68/4885KDM4E 4076/4885MAPT 38/4885 |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | DNMT1, FANCI, PCNA | NPC1 4724/4885KDM4E 2182/4885MAPT 3501/4885 |
| US-20110166198-A1 | RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE | EIF2AK2, IRF3, NSUN2 | NPC1 3157/4885KDM4E 2930/4885MAPT 3977/4885 |
| US-20120107272-A1 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | IFNAR1, DDX18, STING1 | NPC1 3348/4885KDM4E 3656/4885MAPT 4731/4885 |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | NPC1 4730/4885KDM4E 1948/4885MAPT 3723/4885 |
| US-20170283801-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | NPC1 193/4885KDM4E 3864/4885MAPT 3036/4885 |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | NPC1 4730/4885KDM4E 1948/4885MAPT 3723/4885 |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | NPC1 4457/4885KDM4E 1792/4885MAPT 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.